Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.

Shionogi approved the acquisition of IntraBio Inc. for $2 billion to expand its rare disease portfolio, gaining global rights to AQNEURSA, a treatment for Niemann-Pick disease Type C and Ataxia-Telangiectasia, enhancing its pipeline in rare neurodegenerative diseases.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 5 Oct 2026 and 6 Oct 2026.